Yet another MS drug fails to do any better than placebo in humans.

When will the MS specialists and drug makers realize that

EAE does not equal MS.

How much more money and time are we going to waste?

How many more experiments on those with MS?

Here is a wonderfully optimistic paper on how laquinimod healed the mice:

Insight into the mechanism of laquinimod action.

Brück W, Wegner C.

Abstract

Orally administered laquinimod was found to be present within the central nervous system (CNS) in both healthy mice and mice with experimental autoimmune encephalomyelitis (EAE). Laquinimod inhibits development of both acute and chronic EAE. Furthermore, laquinimod minimizes inflammation, demyelination and axonal damage in MOG-induced EAE in mice treated at disease induction and following clinical disease onset. 

 http://www.ncbi.nlm.nih.gov/pubmed/21429524

And here is the reality today....reported, not in medical journals, but in the financial papers.  Because curing mice and making money is what this game is all about.....

Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug.

“Laquinimod is dead, if not regulatorily, then commercially,” Ori Hershkovitz, a partner at Sphera Funds Management Ltd. in Tel Aviv, said by e-mail. Sphera doesn’t have a position in Teva shares.

Teva’s ADRs fell $3.11, or 6.7 percent, to $43.53 at 11:40 a.m. in New York. They dropped as much as 7.8 percent, the biggest intraday decline since April 21. Active Biotech AB (ACTI), which is developing laquinimod with Teva, fell the most in at least 19 years, according to Bloomberg data.

http://www.bloomberg.com/news/2011-08-01/teva-s-oral-multiple-sclerosis-drug-fails-to-meet-goal-of-clinical-trial.html